$INSM

Analysts from Monness and J.P. Morgan maintained Buy ratings on Meta Platforms (META) with price targets of $830 and $820, respectively. Micron (MU) received a Buy rating and $1540 price target from J.P. Morgan. Insmed (INSM) was rated Buy with a $175 target by J.P. Morgan. All three stocks have Strong Buy consensus ratings.

Insmed (INSM) announced the FDA granted priority review for its ARIKAYCE lung drug, setting a January 2027 decision date. The application seeks full approval for broader use in treating MAC lung disease. Clinical trial results showed significant improvements in respiratory symptoms and bacterial conversion rates. Success could expand the patient pool and increase revenue, but regulatory, tolerability, and commercialization risks remain.

FDA granted Priority Review to Insmed's sNDA for Arikayce to treat MAC lung disease. Sotatercept's label updated with HYPERION trial data. Celldex's barzolvolimab met endpoints in CSU trials. Eli Lilly's Onswik approved for type 2 diabetes. Gazyva approved for idiopathic nephrotic syndrome.

Goldman Sachs initiated coverage on Insmed Inc. (NASDAQ:INSM) with a buy rating and a $188 price target, citing strong revenue growth and high gross margins. The company's revenue grew 186% to $1.14 billion over the last twelve months, with analysts projecting continued sales growth. Management expects peak sales of over $14 billion across its lead assets. The FDA granted priority review for Arikayce's expanded use, and the company received regulatory approval for Brinsupri in Japan.

Insmed (INSM) announced FDA Priority Review for ARIKAYCE in MAC lung disease, based on positive Phase 3b ENCORE trial results. The company projects $4.1B revenue and $1.0B earnings by 2029, with ARIKAYCE potentially expanding its rare disease portfolio. Analysts' views vary, with some forecasting slower uptake. The FDA decision is expected by January 28, 2027.

Insmed Inc. (NASDAQ:INSM) shares rose 2% premarket after the FDA granted priority review to its sNDA for Arikayce, targeting MAC lung disease. The FDA set a review deadline of January 28, 2027. Arikayce, approved in 2018, could see expanded use if the application succeeds. The sNDA is backed by Phase 3b ENCORE study results showing significant improvements in respiratory symptoms and culture conversion.

Insmed Inc. (INSM) announced the FDA granted Priority Review to its sNDA for ARIKAYCE to treat MAC lung disease, with a PDUFA action date of January 28, 2027. The application is based on positive Phase 3b ENCORE study results, which showed significant improvements in respiratory symptoms and culture conversion. Full approval could expand ARIKAYCE's use to earlier-stage patients. The FDA initially approved ARIKAYCE in 2018 under accelerated pathways for refractory MAC lung disease.

Insmed director David R. Brennan sold 25,000 shares at $124 each, totaling $3.1M. He now directly owns 39,238 shares and indirectly owns 60,000 via a trust. The transaction was reported in an SEC Form 4 filing.

Brennan David R sold 25,000 shares of INSMED Inc (INSM) at $124.00 ($3.10M total) on 2026-09-09.

Insmed (INSM) shares rose 3.1% today, likely due to positive investor conference messaging and strong respiratory franchise momentum. Management raised peak sales outlook to over $14B and adjusted 2026 BRINSUPRI revenue guidance to $1.25B-$1.40B. The company reported $1.2B in cash as of June 30, 2026.